Spots Global Cancer Trial Database for renal cell cancer metastatic
Every month we try and update this database with for renal cell cancer metastatic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. | NCT04749602 | Renal Cell Canc... Non-small Cell ... Pleural Effusio... | Nivolumab | 18 Years - | Kidney Cancer Research Bureau | |
| A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC | NCT03876925 | Renal Cell Canc... | CT053PTSA | 18 Years - 75 Years | Sunshine Lake Pharma Co., Ltd. | |
| 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer | NCT01658813 | Gastrointestina... Renal Cell Canc... Non Small Cell ... | 5-Fluorouracil ... | 18 Years - | Western Regional Medical Center | |
| Interleukin-2 in Metastatic Kidney Cancer | NCT01702909 | Renal Cell Canc... Kidney Cancer M... | Interleukin-2 | 18 Years - | Western Regional Medical Center | |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | NCT03634540 | Renal Cell Carc... Clear Cell Rena... Kidney Cancer Renal Cancer Renal Cell Carc... Renal Cell Canc... Renal Cell Carc... Renal Cell Canc... Kidney | Belzutifan Cabozantinib | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Sunitinib Treatment on Tissue Sodium Accumulation (TSS2) | NCT04368546 | Renal Cell Canc... Hypertension Sodium Imbalanc... | Sunitinib | 18 Years - 70 Years | Charite University, Berlin, Germany | |
| CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma | NCT03095040 | Renal Cell Canc... | CM082 combined ... CM082 Everolimus | 18 Years - 75 Years | AnewPharma | |
| 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer | NCT01658813 | Gastrointestina... Renal Cell Canc... Non Small Cell ... | 5-Fluorouracil ... | 18 Years - | Western Regional Medical Center | |
| A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC | NCT03876925 | Renal Cell Canc... | CT053PTSA | 18 Years - 75 Years | Sunshine Lake Pharma Co., Ltd. | |
| Sunitinib Treatment on Tissue Sodium Accumulation (TSS2) | NCT04368546 | Renal Cell Canc... Hypertension Sodium Imbalanc... | Sunitinib | 18 Years - 70 Years | Charite University, Berlin, Germany | |
| Sunitinib Treatment on Tissue Sodium Accumulation (TSS2) | NCT04368546 | Renal Cell Canc... Hypertension Sodium Imbalanc... | Sunitinib | 18 Years - 70 Years | Charite University, Berlin, Germany | |
| National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC) | NCT05326620 | Renal Cancer Renal Cell Carc... Renal Cell Canc... | 18 Years - | PROspective Renal Cancer Cohort Foundation | ||
| A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | NCT04903873 | Solid Tumor Renal Cell Canc... Non-Small Cell ... Renal Cell Carc... Prostate Cancer | EU101 | 18 Years - | Eutilex | |
| CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma | NCT03095040 | Renal Cell Canc... | CM082 combined ... CM082 Everolimus | 18 Years - 75 Years | AnewPharma | |
| A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | NCT04903873 | Solid Tumor Renal Cell Canc... Non-Small Cell ... Renal Cell Carc... Prostate Cancer | EU101 | 18 Years - | Eutilex | |
| CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma | NCT03095040 | Renal Cell Canc... | CM082 combined ... CM082 Everolimus | 18 Years - 75 Years | AnewPharma | |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | NCT03634540 | Renal Cell Carc... Clear Cell Rena... Kidney Cancer Renal Cancer Renal Cell Carc... Renal Cell Canc... Renal Cell Carc... Renal Cell Canc... Kidney | Belzutifan Cabozantinib | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
